ABIOMED, Inc. (NASDAQ:ABMD) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $147.00.

Several analysts have commented on ABMD shares. TheStreet cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Thursday, October 27th. Zacks Investment Research raised shares of ABIOMED from a “sell” rating to a “hold” rating in a research note on Monday, January 30th. Guggenheim started coverage on shares of ABIOMED in a research note on Tuesday, December 6th. They issued a “buy” rating and a $150.00 target price for the company. Finally, BTIG Research reaffirmed a “buy” rating and issued a $170.00 target price on shares of ABIOMED in a research note on Sunday, January 8th.

ABIOMED (NASDAQ:ABMD) opened at 114.25 on Tuesday. ABIOMED has a 12-month low of $78.46 and a 12-month high of $132.95. The company has a 50-day moving average price of $110.97 and a 200 day moving average price of $116.57. The stock has a market cap of $4.96 billion, a price-to-earnings ratio of 106.88 and a beta of 0.51.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, January 26th. The company reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.05. The firm earned $114.70 million during the quarter, compared to analysts’ expectations of $112.71 million. ABIOMED had a net margin of 11.63% and a return on equity of 12.35%. ABIOMED’s revenue for the quarter was up 33.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.23 EPS. On average, equities research analysts predict that ABIOMED will post $1.18 EPS for the current year.

This report was posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright laws. The original version of this report can be viewed at http://www.watchlistnews.com/analysts-set-abiomed-inc-abmd-price-target-at-147-00/1121695.html.

In other news, Director Dorothy E. Puhy sold 8,000 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $120.00, for a total transaction of $960,000.00. Following the completion of the sale, the director now directly owns 32,749 shares of the company’s stock, valued at approximately $3,929,880. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of ABIOMED by 320.1% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 8,272 shares of the company’s stock valued at $1,064,000 after buying an additional 6,303 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of ABIOMED by 4.3% in the third quarter. BlackRock Fund Advisors now owns 1,631,879 shares of the company’s stock valued at $209,827,000 after buying an additional 66,809 shares in the last quarter. IronBridge Capital Management LP boosted its stake in shares of ABIOMED by 4.2% in the third quarter. IronBridge Capital Management LP now owns 35,106 shares of the company’s stock valued at $4,514,000 after buying an additional 1,406 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of ABIOMED by 1.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,177,198 shares of the company’s stock valued at $151,364,000 after buying an additional 16,224 shares in the last quarter. Finally, American International Group Inc. boosted its stake in shares of ABIOMED by 1.6% in the third quarter. American International Group Inc. now owns 77,023 shares of the company’s stock valued at $9,904,000 after buying an additional 1,190 shares in the last quarter. 92.67% of the stock is owned by institutional investors.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

5 Day Chart for NASDAQ:ABMD

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.